



Uscom

ASX MEDIA RELEASE

Uscom China Ranked AAA Credit Enterprise

- Recognition of Uscom by China Credit Enterprise Publicity Network
- Benefits domestic tenders, government grants and commercial partnerships
- Uscom China also listed as China National High Technology Enterprise
 - Uscom China rapidly growing and leading global subsidiary

SYDNEY, Australia, Monday 5th July 2021: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) today notified the market that Uscom China, a wholly owned subsidiary of Uscom Limited, has been recognised as a AAA Credit Enterprise by China Credit Enterprise Publicity Network.

AAA (the highest credit ranking) is granted to Uscom China according to GB/T23794-2015 standard, based on the company's credit record, operating conditions, debt risks, development prospect, social comments and public recognition. The credit ranking is formally announced to the society after the all-round strict and comprehensive assessment. The certificate is valid for three years to June 8th 2024.

Uscom China got AAA ranking for its awareness of quality, service, contracts, and credibility, and is honored as "Enterprise with Integrity for Quality and Service" and "Sample Site of Business with Integrity". The AAA ranking improves credibility to some tenders and Government grants, and demonstrates strengths to support strategic partnership with manufacturers and distributors.

Background:

Uscom has operated in China for over 15 years, and in 2018 opened its wholly owned Uscom China subsidiary in Beijing, appointing Ms Teresa Guo as General Manager. This award further recognises the talent of the management in Uscom China as it has rapidly evolved to be Uscom's fastest growing and largest global subsidiary establishing a rapidly expanded sales and distribution network and delivering the USCOM 1A into China's regional hospitals. The non-invasive ultrasonic Doppler hemodynamic monitor (featured by USCOM 1A) was recommended as a preferred method for management of severe COVID-19 infection by National Health Commission of PRC, and USCOM 1A was used in more than 56 COVID-19 designated China hospitals.

Operations:

Uscom China has registered 12 Software Copyrights, 13 Trademarks, and 4 trademark Copyrights with the National Copyright Administration of the People's Republic of China, protecting Uscom's core technologies and algorithms in the Chinese market. Uscom China was



Uscom

ASX MEDIA RELEASE

awarded National High Technology Enterprise status by the High Torch branch of the PRC Ministry of Science and Technology in December 2020.

Uscom also received NMPA approval for sale of its patent protected BP+ into the Chinese market in May, and is currently identifying specialised sales teams in preparation for China and international marketing. Uscom China has recently lodged NMPA applications for two new Uscom monitors, the O2 and the Basic monitors designed for advanced and entry level digital ultrasonic cardiovascular monitoring, and the Uscom SpiroSonic devices. These are expected to be NMPA approved over the next 12-18 mths.

Commentary:

Executive Chairman of Uscom, Professor Rob Phillips said *“Uscom’s business in China continues to grow and Uscom is being encouraged by the Chinese authorities to develop a leading medical technology and commercial enterprise. We have invested in our business in China and it is gratifying to see this high level recognition from Chinese agencies. Having both Mr Meng as a Non-Executive Board member and Ms Guo as our China GM ensures we have direct contact with the market, and, combined with strong local support, promotes our continued growth in China and globally. Uscom is being recognised as we plan the development of new technologies and devices.”*

Uscom devices:

Uscom manufactures and markets the **USCOM 1A** haemodynamic monitor, the Uscom **BP+**, central blood pressure and vascular health monitor, the Uscom **SpiroSonic** digital ultrasonic spirometers, and the **VENTITEST** ultrasonic ventilator calibrators for optimising respiratory device performance.

References:

Wang Xiaomei. "Mapping Science Structure 2021". The Chinese Academy of Sciences' Institutes of Science and Development. 2nd May 2021

<http://www.chinadaily.com.cn/a/202105/01/WS608c9670a31024ad0babba3c.html>



Uscom

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM): An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A: A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+: A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary **BP+ Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers: High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone apps and proprietary SpiroSonic software, **SpiroReporter**, with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, occupational lung disease and monitoring of pulmonary therapeutic compliance.

VENTITEST digital ultrasonic ventilator testing solution is a new system for testing ventilators. All ventilators require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. VENTITEST and VENTITEST-S, based on advanced SpiroSonic technology provides a testing solution that provides for simple and accurate testing, archiving, analysis and reporting to optimise ventilation performance.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips
Chairman
rob@uscom.com.au

Brett Crowley
Company Secretary